Company profilePharmaceutical#111 of 1,318 in Pakistan1 DRAP alert

SANOFI AVENTIS (PAKISTAN) LTD.

Pharmaceutical company · 143 brands · 166 molecules

Ranked #8 of 137 companies in Anti-Infectives

143 registered products 42 pharmaceutical brands 166 distinct molecules 1 DRAP alert

Company overview

143

registered products

pharmaceutical brands

166

distinct molecules

therapeutic classes

DRAP alerts

SANOFI AVENTIS (PAKISTAN) LTD. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 143 product registrations across 166 distinct molecules. It is the 111th largest registrant in Pakistan by product count, and ranks 8th of 137 in Anti-Infectives. Its portfolio is concentrated in Anti-Infectives and Vaccine. DRAP has issued 1 alert involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by SANOFI

169 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Anti-Infectives 18

ClaforanRs 110.39 Claforan500mgRs 166.3 Claforan1gRs 276 Claforan2gRs 276 Claforan0.5gRs 276 Claforan250mgRs 110.39 Claforan0.25gRs 276 Flagyl400MgRs 45.2 Flagyl120Ml 200Mg/5MlRs 147.26 Flagyl500Mg 100MlRs 196.57 Flagyl320mgceiling Rs 124.2 Flagyl200mgceiling Rs 534.8

Blood Glucose Lowering Drugs, Excluding Insulin 10

Amarylm500mgRs 438.3 Daonilm5mgRs 120 Emjard-L5Mg 10MgRs 482.86 Emjard-L5Mg 25MgRs 681.38 Emjard-M5Mg 500MgRs 171.5 Emjard-M5Mg 1000MgRs 182.63 Emjard-M500MgRs 221.41 Emjard-M1000mgRs 234.64 Emjardl5mgRs 508.31 Emjardm5mgRs 180.5

Blood Conditions 10

Clexane4000Iu/0.4MlRs 1,610.18 Clexane6000Iu/0.6mlRs 2,526 Clexane8000Iu/0.8mlRs 2,766.46 Clexane8000iuRs 2,766.46 Clexane60mgRs 1,199.7 Clexane4000iuRs 1,694.92 Clexane40mgRs 936.26 Clexane80mgRs 1,405.72 Clexane6000iuRs 2,526 Co-Plavix75MgRs 508.7

Cardiac Care 9

Aprovel150MgRs 822.5 Aprovel300MgRs 2,467.64 Co-Aprovel12.5MgRs 843.08 Co-Aprovel12.5MgRs 1,254.26 Co-Aprovel25mgRs 1,264.62 Co-Tritace5mg 25mgRs 359.1 Cotritace5mgRs 359.1 Cotritace25mgRs 778.4 Cotritace12.5mgRs 592.2

Diabetes 6

Amaryl2MgRs 721.8 Amaryl4MgRs 687.75 Amaryl1MgRs 189.9 Amaryl3MgRs 543.9 Apidraoptisetsolostar100iuRs 4,360 Daonil5mgRs 313.8

Other Beta-Lactam, Cephalosporins & Penems 5

Aventriax1gmRs 603.25 AventriaxRs 603.25 Aventriax250mgRs 603.25 Aventriax1gRs 603.25 Aventriax500mgRs 603.25

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

ceilings with an approval date

not revised in 2+ years

2025

oldest approval year

20257

202644

Top molecules by brand count

Promethazine6 brands

Metformin5 brands

Hydrochlorothiazide4 brands

Pholcodine3 brands

Influenza Vaccine3 brands

Carbocisteine3 brands

Poliomyelitis Vaccine3 brands

Alfuzosin3 brands

Insulin Glargine3 brands

Ramipril3 brands

Therapeutic classes

Conditions treated

Price band (DRAP official ceilings)

Registered products priced by source

DRAP-official16 products · Rs 79.19 – Rs 17,604.11

DVAGO56 products · Rs 36.94 – Rs 5,885.25

Servaid105 products · Rs 34 – Rs 5,961.06

Median across source: Rs 463.64

Regulatory record

1 alert in the DRAP feed we track.

Regulatory Update / Advisory; Recall of Targocid 200mg powder for solution for injection/i

2022-10-31

Competitive set

Companies whose registered portfolio overlaps most with this one.

SEARLE PAKISTAN (PVT.) LTD.30 shared molecules

Wilshire Laboratories (Private) Limited28 shared molecules

SCOTMANN PHARMACEUTICALS25 shared molecules

Werrick Pharmaceuticals Pakistan25 shared molecules

WILSONS PHARMACEUTICALS24 shared molecules

BOSCH PHARMACEUTICALS (PVT) LTD.24 shared molecules

Atco Pharma International (Pvt) Ltd23 shared molecules

MACTER INTERNATIONAL (PVT) LTD.23 shared molecules

IRZA PHARMA (PVT) LTD.23 shared molecules

GETZ PHARMA PAKISTAN (PVT) LTD.23 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

SEARLE PAKISTAN (PVT.) LTD. holds 213 molecules not in this portfolio

Wilshire Laboratories (Private) Limited holds 112 molecules not in this portfolio

SCOTMANN PHARMACEUTICALS holds 82 molecules not in this portfolio

Get the full profile for SANOFI

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included